Liver cancer hope: triple therapy shows promise in early trial
NCT ID NCT07543510
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of low-dose bevacizumab and atezolizumab (immunotherapy drugs) plus targeted chemotherapy delivered directly to the liver (TACE-HAIC) as a first treatment for people with unresectable hepatocellular carcinoma. About 38 participants will receive this approach to see if it shrinks tumors and delays progression. The goal is to improve on current standard therapy, which has limited effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab and atezolizumab (immunotherapy and anti-angiogenic drugs) combined with chemotherapy delivered directly to the liver
What this could lead to
If successful, this combination could improve tumor shrinkage and delay cancer progression in people with advanced liver cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (38 people) with no comparison group, so results may not be definitive. The combination also carries risks like bleeding, liver damage, and immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••